Format

Send to

Choose Destination
Nucl Med Biol. 2018 Nov;66:10-17. doi: 10.1016/j.nucmedbio.2018.08.001. Epub 2018 Aug 9.

Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE.

Author information

1
Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada; Département de Médecine Nucléaire et Radiobiologie, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
2
Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada.
3
Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada; Department of Radiology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada. Electronic address: klin@bccrc.ca.
4
Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada; Department of Radiology, University of British Columbia, Vancouver, BC V5Z 1M9, Canada. Electronic address: fbenard@bccrc.ca.

Abstract

INTRODUCTION:

[177Lu]Lu-DOTATATE peptide receptor radionuclide therapy is used for treatment of neuroendocrine tumours. We investigated whether prolonging blood residence time of [177Lu]Lu-DOTATATE with albumin binders could increase tumour accumulation and tumour-to-kidney ratios for improved therapeutic efficacy.

METHODS:

DOTATATE and its derivatives with an albumin-binder motif (GluAB-DOTATATE and AspAB-DOTATATE) were prepared by solid-phase peptide synthesis. Binding affinities of the Lu-labeled peptides for human somatostatin receptor 2 (SSTR2) were measured with membrane competition binding assays. Compounds were radiolabeled with [177Lu]LuCl3 and purified by HPLC. SPECT imaging and biodistribution studies (1, 4, 24, 72, and 120 h) were performed in immunodeficient mice bearing AR42J pancreatic tumour xenografts.

RESULTS:

GluAB-DOTATATE and AspAB-DOTATATE were synthesized in 18.8% and 14.3% yields, while Lu-GluAB-DOTATATE and Lu-AspAB-DOTATATE were obtained in 86.5% and 50.0% yields, respectively. The compounds exhibited nanomolar binding affinity (Ki: 8.72-8.95 nM) for SSTR2. The 177Lu-labeled peptides were obtained in non-decay-corrected isolated yields of ≥41%, with >96% radiochemical purity, and molar activities in the range of 314-497 GBq/μmol. In vivo, [177Lu]Lu-GluAB-DOTATATE and [177Lu]Lu-AspAB-DOTATATE had significantly higher blood activity at 1, 4 and 24 h compared to [177Lu]Lu-DOTATATE. Tumour uptake of [177Lu]Lu-DOTATATE was 21.35 ± 5.90%ID/g at 1 h and decreased to 10.10 ± 5.78%ID/g at 120 h. For [177Lu]Lu-GluAB-DOTATATE tumour uptake increased from 21.89 ± 6.86%ID/g at 1 h to 24.44 ± 5.84%ID/g at 4 h, before decreasing to 12.02 ± 1.84%ID/g at 120 h. For [177Lu]Lu-AspAB-DOTATATE tumour uptake was 11.12 ± 3.18%ID/g at 1 h, 18.41 ± 4.36%ID/g at 24 h, and decreased to 16.90 ± 8.97%ID/g at 120 h. Renal uptake was 7.49 ± 1.62%ID/g for [177Lu]Lu-DOTATATE, 31.14 ± 7.06%ID/g for [177Lu]Lu-GluAB-DOTATATE, and 28.82 ± 13.82%ID/g for [177Lu]Lu-AspAB-DOTATATE at 1 h and decreased thereafter.

CONCLUSION:

The addition of albumin binder motifs to [177Lu]Lu-DOTATATE enhanced mean residence time in blood. Increased tumour uptake was observed for [177Lu]Lu-AspAB-DOTATATE compared to [177Lu]Lu-DOTATATE at later time points, but its higher kidney uptake diminished the therapeutic index.

KEYWORDS:

Albumin binder; DOTATATE; Dosimetry; Neuroendocrine tumour; Peptide receptor radionuclide therapy; Therapy

PMID:
30170196
DOI:
10.1016/j.nucmedbio.2018.08.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center